HomeBUSINESS
BUSINESS

I/O in Lung Cancer - 7: Oncologist Sees Promise in I/O-I/O Combos, Prods Quest for Cure
(Oct.5.2018)

Yuichiro Ohe, MD, Deputy Director, Chief, Department of Thoracic Oncology, National Cancer Center Hospital
By Takashi Ebisawa

Keytruda (pembrolizumab) obviously has a big edge in the immuno-oncology race for the treatment of lung cancer, but people should not downplay the benefit of the Opdivo (nivolumab)/Yervoy (ipilimumab) combo in terms of long-term survival, a prominent oncologist tells Jiho. To wrap up this series, Yuichiro Ohe of the National Cancer Center puts recent I/O trial data into perspective ...
(LOG IN FOR FULL STORY)